SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
-12.36%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$268M
AUM Growth
+$268M
(-2%)
Cap. Flow
+$34.6M
Cap. Flow
% of AUM
12.9%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Mineralys Therapeutics
MLYS
|
$28.1M |
| 2 |
ARS Pharmaceuticals
SPRY
|
$6.53M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $169M | 63.12% |
5,500,007
| – | – |
|
2
Design Therapeutics
DSGN
$315M
| $37.7M | 14.03% |
6,526,476
| – | – |
|
|
3
Mineralys Therapeutics
MLYS
$1.03B
| $28.1M | 10.47% |
+1,794,600
| New | +$28.1M |
|
|
4
ARS Pharmaceuticals
SPRY
$1.15B
| $26.1M | 9.73% |
4,012,903
+1,003,226
| +33% | +$6.53M |
|
5
Nkarta
NKTX
$151M
| $4.73M | 1.76% |
1,333,333
| – | – |
|
|
EFTR
6
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $2.39M | 0.89% |
6,822,114
| – | – |
|